Skip to Main Content

INFORMATION FOR

Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD (ASCENT ASD)

Conditions

Diseases of the Cardiovascular System | Genetics - Pediatric

What is the purpose of this trial?

Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect.

  • Trial with
    CARAG, LLC
  • Start Date
    11/11/2021
  • End Date
    09/30/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000029209